To provide you with a better experience, our website uses cookies. To continue browsing, you please accept our cookies policy.


Cookies informations

Our site uses tools, such as cookies, to analyse and improve your experience. You can unsubscribe from these follow-ups:


Nous utilisons des outils, tels que Google Analytics, pour suivre le trafic Web et vérifier l'efficacité de notre site.


Cookies requis pour les services essentiels et les fonctionnalités telles que les formulaires de connexion, l'intégration du panier et le contrôle d'accès. Sans eux, notre site Web ne peut pas fonctionner correctement et nous ne pouvons fournir aucun service. La désactivation n'est pas disponible.

These parameters will be stored for 24 hours

for life

Excellence dedicated to nuclear medicine,
healthcare and environment.

More about us

Our departments

One group, two entities

IRE, world leader in the production of radioisotopes and its prevention division, IRE Lab

IRE ELiT Radiopharma, a laboratory of ideas and actions for radiopharmaceutical innovation

Our figures

Our figures

IRE is one of the leaders in the production of molybdenum (99Mo) for the manufacture of technetium-99m (99mTc) generators.

IRE ELiT is one of the only two global suppliers of germanium-68 (68Ge) / gallium-68 (68Ga) generators to have been approved as a drug in Europe and as an Active Pharmaceutical Ingredient in the United States.

Our history

Can benefit from a medical examination each year thanks to radioisotopes produced at IRE

100MTurnoveren 2019
230Employees including
30 at IRE ELiT
15%Of turnover
reinvested in R&D


The values of our company are the moral principles we set for ourselves in the performance of our activities. They shape our corporate culture.

IRE moves to 100% LEU (Low-Enriched Uranium) conversion

Fleurus, Belgium, March 28th, 2023 – The Institute for Radioelements (IRE), world leader in the production of molybdenum-99 (Mo-99), the most widely used radioisotope in nuclear medicine for diagnosis, and iodine-131 (I-131) essential and irreplaceable radionuclide for thyroid cancer treatments, announced today the complete conversion of its production process to low-enriched uranium (LEU).

Ground-breaking ceremony for RECUMO

From 2026 onwards, the nuclear research centre SCK CEN will transform radioactive residues into low-enriched uranium and will purify them in its brand new RECUMO facility. These residues resulting from the production of medical radioisotopes on the site of the Institut National des Radioéléments (IRE). Today, the first sod was turned for the RECUMO building. With it, IRE and SCK CEN are literally creating a European first on Belgian soil.

The fight against cancer intensified thanks to SCK CEN and the IRE

SCK CEN, the Belgian Nuclear Research Centre, and the National Institute for Radioelements (IRE) are going to start the large-scale production of lutetium-177. This decision, validated today by the signature of the two partners, opens up opportunities for cancer patients. Among other things, this radioisotope is very promising for the treatment of prostate cancer. This type of cancer is responsible for 90,000 deaths each year in Europe.

SMART takes critical step towards the production of medical isotope Mo-99 without uranium

Fleurus, 22 February 2022 – Since 2018, the National Institute for Radioelements (IRE) has been working with the Dutch company ASML on the SMART project. Its goal: to develop a new technology to produce a radioisotope that is crucial to nuclear medicine, without using uranium. February 2022 marks a turning point in the future of this ambitious project since a proof of concept test has recently validated the main principles of this unprecedented technology. This is a major step in the design and engineering phase, the success of which will allow confirmation of technical choices during 2022 in preparation for the Board of Directors’ decision regarding investment in an industrial facility.

First commercial deliveries of I-131 based on LEU from IRE plant

Fleurus, Belgium 1st February 2021 - IRE is pleased to announce that its first commercial deliveries of I-131 based on the irradiation of Low Enriched Uranium (LEU) targets have started this week.